CN104367725A - Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases - Google Patents
Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN104367725A CN104367725A CN201410626346.2A CN201410626346A CN104367725A CN 104367725 A CN104367725 A CN 104367725A CN 201410626346 A CN201410626346 A CN 201410626346A CN 104367725 A CN104367725 A CN 104367725A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- blood
- fluoritum
- parts
- herba erigerontis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
Abstract
The invention discloses an erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition is mainly prepared from fructus choerospondiatis, erigeron breviscapus, amethyst, saffron and ginseng leaves. The pharmaceutical composition can be used for promoting blood circulation to dispel blood stasis and invigorating Qi to promote blood circulation and has a better treatment effect on ischemic cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, specifically Fructus Choerospondiatis, Herba Erigerontis, Fluoritum, Stigma Croci, Folium Ginseng are the pharmaceutical composition that raw material is made.
Background technology
Cardiovascular and cerebrovascular disease is middle-aged and elderly people common disease, and especially old people's sickness rate of more than 60 years old is high, and it is long that high fat of blood sends out the time, and greatly, being difficult to radical cure, is one of Etiological that person in middle and old age's cardiovascular and cerebrovascular disease is lethal in blood viscosity change.The traditional Chinese medical science thinks taste virtual loss, dysfunction of the spleen in transportation and transformation, causes that expectorant is turbid to be gathered, qi depression to blood stasis.Wherein empty in QI and blood, be induce into this cause of the hyperlipidemia, because of patient's blood stasis due to qi deficiency, QI and blood is not all right and phlegm-turbidity and blood stasis is stagnant.Middle-aged and elderly people visceral-qi void declines, dysfunction of the spleen in transportation and transformation, and easy in blood expectorant is turbid gathers, and long-pending sick solid for a long time, in daily life once burst thromboembolism, is usually fatal.Though thromboembolism morbidity is at blood vessel, the right cause of disease regulates unstability by the five internal organs six mansion, and expectorant is turbid to be gathered, and phlegm-damp blood stasis is stagnant in middle Jiao, caused by functional activity of QI being not smooth.Its essence is weakened body resistance, and namely yang-energy is not changed, and heresy is life thus, comes and goes with gas.
Summary of the invention
Object of the present invention is just to provide a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, and this pharmaceutical composition can healthy energy, and Eradicates is empty, promoting blood circulation to restore menstrual flow, promotes the mutual transporting between body fluid and QI and blood, patient is got well.
In order to realize foregoing invention object, the invention provides following technical scheme:
Treat a pharmaceutical composition for cardiovascular and cerebrovascular disease, it is raw material composition primarily of Fructus Choerospondiatis, Herba Erigerontis, Fluoritum, Stigma Croci, Folium Ginseng.
Chinese medicine composition tranquilizing by nourishing the heart of the present invention, tonifying vital QI, promoting flow of QI and blood, expelling wind and removing dampness, activating collaterals to relieve pain.Increase the transporting between dirty mansion body fluid and QI and blood, invigorating blood circulation bolt, effectively treats cardiovascular and cerebrovascular disease, prevents disease relapse, is particularly useful for high thrombosis class cardiovascular and cerebrovascular disease.Preferably only adopt above five kinds of compositions.
Preferably, in pharmaceutical composition of the present invention, the ratio of each component is: Fructus Choerospondiatis 1-20 part, Herba Erigerontis 1-6 part, Fluoritum 1-10 part, Stigma Croci 1-6 part, Folium Ginseng 1-30 part.Folium Ginseng and Stigma Croci tonifying QI to produce body fluid, active blood stasis dispelling, Fluoritum relieving palpitation dispersing stagnation and relieving accumulation of pathogens, is aided with the dehumidifying of Herba Erigerontis Eradicates wind, Fructus Choerospondiatis tranquilizing by nourishing the heart.Supply vigour, unobstructed meridians, transporting essence and blood, dispels severe pathogenic cold, effectively treats cardiovascular and cerebrovascular disease, and regulates self body constitution of patient, and prevent transporting solid stagnant, blood stasis recurs.Realize the collaborative facilitation between kinds of traditional Chinese medicines, improve the body constitution of patient and the power of meridians transporting greatly, improve the effect for the treatment of cardiovascular and cerebrovascular disease.
Preferably, in pharmaceutical composition of the present invention, the ratio of each component is: Fructus Choerospondiatis 5-15 part, Herba Erigerontis 1-5 part, Fluoritum 3-8 part, Stigma Croci 1-5 part, Folium Ginseng 10-20 part.In conjunction with the proportioning of the preferred each component of clinical research experience, improve mutual promoting action, reduce the toxic and side effects that medicine is unnecessary.
Most preferred, in pharmaceutical composition of the present invention, the ratio of each component is: Fructus Choerospondiatis 9 parts, Herba Erigerontis 3 parts, Fluoritum 6 parts, Stigma Croci 3 parts, Folium Ginseng 15 parts.Select the Chinese medicine composition proportioning of aforementioned proportion, best at therapeutic effect, after medication, patient gets well fast, and QI and blood transporting is smooth and easy, and blood stasis no longer recurs.
The cardiovascular and cerebrovascular disease that medicine of the present invention is controlled mainly comprises cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, nerve injury, senile dementia, parkinsonism etc.Be particularly useful for the prevention and therapy of ischemia apoplexy.
Compared with prior art, beneficial effect of the present invention:
Chinese medicine composition tranquilizing by nourishing the heart of the present invention, tonifying vital QI, promoting flow of QI and blood, expelling wind and removing dampness, activating collaterals to relieve pain.Increase the transporting between dirty mansion body fluid and QI and blood, invigorating blood circulation bolt, effectively treats cardiovascular and cerebrovascular disease, prevents disease relapse, is particularly useful for high thrombosis class cardiovascular and cerebrovascular disease.
Folium Ginseng and Stigma Croci tonifying QI to produce body fluid, active blood stasis dispelling, Fluoritum relieving palpitation dispersing stagnation and relieving accumulation of pathogens, is aided with the dehumidifying of Herba Erigerontis Eradicates wind, Fructus Choerospondiatis tranquilizing by nourishing the heart.Supply vigour, unobstructed meridians, transporting essence and blood, dispels severe pathogenic cold, effectively treats cardiovascular and cerebrovascular disease, and regulates self body constitution of patient, and prevent transporting solid stagnant, blood stasis recurs.Realize the collaborative facilitation between kinds of traditional Chinese medicines, improve the body constitution of patient and the power of meridians transporting greatly, improve the effect for the treatment of cardiovascular and cerebrovascular disease.
Detailed description of the invention
Pharmaceutical composition of the present invention, the method by oral, external, injection, infiltration, absorption, physics or chemistry mediation imports body as muscle, Intradermal, subcutaneous, vein or mucosal tissue; Or to be mixed by other material or to import body after wrapping up.
Further, pharmaceutical composition of the present invention, adds medicine acceptable carrier or adjuvant when being prepared into medicament, make pharmaceutically acceptable dosage form.
Pharmaceutical composition of the present invention, according to use needs, can by current usual manner, by described active drug composition auxiliary adding ingredient corresponding to acceptable in medicine, as disintegrating agent, excipient, lubricant, binding agent, filler etc., jointly be prepared into operational, comprise the oral type pharmaceutical preparation of the common formulations such as tablet, drop pill, capsule, micropill.
In Chinese medicine composition of the present invention: Fructus Choerospondiatis, sweet in the mouth, acid, property is put down.Promoting flow of QI and blood, nourishes heart, and calms the nerves.For qi depression to blood stasis, the thoracic obstruction is had a pain, shortness of breath and palpitation, irritability.Herba Erigerontis, acrid in the mouth, micro-hardship, warm in nature.Expelling cold and relieving exterior syndrome, expelling wind and removing dampness, activating collaterals to relieve pain.For headache due to common cold, toothache, stomachache, rheumatalgia, the paralysis that cerebrovas-cularaccident causes, osteomyelitis.Fluoritum, sweet in the mouth, warm in nature.Enter the heart, Liver Channel.Relieving palpitation, can control asthenia palpitation with fear, cough with dyspnea, women's sea of blood deficiency and coldness is infertile.Stigma Croci, sweet in the mouth, property is put down, energy blood circulation promoting and blood stasis dispelling, dispersing stagnation and relieving accumulation of pathogens, pain relieving.Be used for the treatment of troubled thoughts pent-up, chest and diaphragm painful abdominal mass is vexed, and spit blood, typhoid fever is gone mad, and frightened fear in a trance, women's amenorrhea, stasis menoxenia, prolonged lochia, blood stasis is had a pain, measles, traumatic injury etc.Folium Ginseng, bitter in the mouth, sweet, cold in nature, return lung, stomach two warp.Have lung heat clearing, promoting the production of body fluid to quench thirst, asthenic fire, falls in invigorating middle warmer band table, the sharp extremity head, effect of tonifying vital QI.
Pharmaceutical composition of the present invention can adopt but be not limited to following methods:
Preparation method one: get Fructus Choerospondiatis, Herba Erigerontis, Fluoritum, Stigma Croci, Radix Ginseng in proportion, mixed after pulverizing 40 mesh sieves respectively, after adding the acceptable auxiliary element of appropriate pharmacy, made the oral type pharmaceutical preparatioies such as tablet, capsule or micropill.
Preparation method two: by Fructus Choerospondiatis, Herba Erigerontis, Stigma Croci and Radix Ginseng alcohol reflux, extracting solution is concentrated into dry, obtains extract one.By Fluoritum pulverizing, cross 60 mesh sieves, obtain Fluoritum powder.By extract one and the mixing of Fluoritum powder, after adding the acceptable auxiliary element of pharmacy as required, make the oral type pharmaceutical preparatioies such as tablet, capsule, drop pill or micropill.
The alcohol reflux 1-3 hour of the 30%-80% of preferred Fructus Choerospondiatis, Herba Erigerontis, Stigma Croci and Radix Ginseng 2-4 times volume, repeat to extract 2-4 time, extracting solution is concentrated into dry, obtains mixed extract one.
Preparation method three:
Prepare the method for Chinese medicine composition of the present invention, comprise the following steps:
(1) getting Fructus Choerospondiatis pulverize at low temperature, to obtain Fructus Choerospondiatis powder for subsequent use.
(2) Herba Erigerontis medical material is got, preferably through the preliminary Herba Erigerontis pulverized, add the high concentration ethanol of 4 ~ 6 times amount, reflux, extract, 1 ~ 2 time, each 1 ~ 2 hour, merge extractive liquid, reclaim ethanol to paste, add 0.1% sodium hydroxide to dissolve, filter, the saturated n-butanol extraction of filtrate water.After water layer regulates pH=2 ~ 3, then with water-saturated n-butanol extraction, merge n-butyl alcohol liquid, be concentrated into dry, obtain Herba Erigerontis extract.
(3) get Fluoritum pulverizing, cross 60 mesh sieves, obtain Fluoritum powder for subsequent use.
(4) get Stigma Croci, add the dense ethanol of 1-2 times of volume, 60-70 DEG C of heating extraction 0.5-2 hour, repeat to extract 4-6 time, merge extractive liquid, reclaim ethanol, centrifugal, discard precipitation, supernatant is evaporated to dry, obtains Stigma Croci extract.
(5) Folium Ginseng, adds soak by water 3-5 time of 5-10 times of volume, each 1-2 hour, collecting decoction, be concentrated into 1/5 ~ 1/3 volume, add ethanol to ethanol content 40%-60%, hold over night or centrifugal, precipitation discards, and supernatant is evaporated to dry, both obtains extract of Radix Ginseng leaf.
(6) the various extracts obtained through above-mentioned steps process are mixed in proportion, make tablet or capsule.The acceptable adjuvant of appropriate pharmacy can be added according to actual needs.
High concentration ethanol of the present invention or dense ethanol refer to the ethanol water of percent by volume more than 60%.Described Diluted Alcohol refers to the ethanol water of percent by volume below 25%.
Wherein most preferably preparation method three, preparation method three is according to different medicines characteristic separately, select suitable extracting method farthest to be extracted by the effective ingredient in medicinal raw material, avoid the impact of the impurity of toxic side effect, so most preferably preparation method three.
The curative effect of medicine of the present invention and advantage thereof are proved by following pharmacodynamics test:
Test one: pharmacodynamics test rat " rabbit brain powder-macromolecule glucosan " being caused to the therapeutical effect of cerebral infarction
Principle: because cardiovascular and cerebrovascular disease all can cause hemorheological change, so medicine causes the therapeutical effect of cerebral infarction pharmacodynamics test to rat " rabbit brain powder-macromolecule glucosan " can be designed, to measure the change that whole blood viscosity under different shear rate investigates hemorheological property after cerebral infarction, investigate erythrocyte deformability with red blood cell protein ringer solution viscosity, thus investigate medicine to the therapeutical effect of cardiovascular and cerebrovascular disease.
Material: animal: rat, body weight 250-350g, male and female are regardless of.Equipment: cone and plate viscometer, centrifuge, scale centrifuge tube, eye scissors, ophthalmic tweezers and conventional operating theater instruments, 0 trumpeter's art silk thread, vascular clamp etc.
Medicine and reagent: application medicine 1:(Fructus Choerospondiatis 9 parts, Herba Erigerontis 3 parts, Fluoritum 6 parts, Stigma Croci 3 parts, Folium Ginseng 15 parts, adopt preparation method three to be prepared into tablet);
Application medicine 2:(Fructus Choerospondiatis 10 parts, Herba Erigerontis 4 parts, Fluoritum 6 parts, Stigma Croci 3 parts, Folium Ginseng 11 parts, adopt preparation method two to be prepared into tablet);
Application medicine 3:(Fructus Choerospondiatis 9 parts, Herba Erigerontis 4 parts, Fluoritum 5 parts, Stigma Croci 3 parts, Folium Ginseng 17 parts.Preparation method one is adopted to be prepared into tablet);
Control drug 1:(Fructus Choerospondiatis 9 parts, Herba Erigerontis 3 parts, Folium Ginseng 15 parts, adopt preparation method two to be prepared into tablet);
Control drug 2:(Herba Erigerontis 3 parts, Fluoritum 6 parts, Stigma Croci 3 parts, Folium Ginseng 15 parts, adopt preparation method one to be prepared into tablet);
Control drug 3:(Fructus Choerospondiatis 9 parts, Herba Erigerontis 3 parts, Stigma Croci 3 parts, Folium Ginseng 15 parts, adopt preparation method two to be prepared into tablet);
With commercially available Breviscapini injection for positive drug contrasts; Rabbit brain powder (rabbit brain powder thromboplastin powder).Get the rabbit brain powder between sub-sieve 120-150 order, granule is 100-120m.Macromolecule glucosan: molecular weight 5,000,000.The preparation of suppository: by 25m
grabbit brain powder is mixed in 10% macromolecule dextran solution 100ml, is placed in 37 DEG C of water-baths 40 minutes.Then ,-18 DEG C of refrigerators are put in for subsequent use.Rapid Medical ZT glue.BSA, ringer solution.Heparin sodium: add test tube by 20u/ml blood dosage, less than 40 DEG C dry for standby.
Test method: 1, rat cerebral infarction model preparation: rat etherization, lie on the back fixing, skin cropping is sterilized, cervical incision, and on the left of being separated, neck always beats one's brains, neck is interior, external carotid artery.Folder closes external carotid artery, common carotid artery proximal part respectively.A vascular clamp is pressed from both sides again at distal end place.After suppository is shaken up, lunge common carotid artery with 0.25ml syringe by 0.03ml/100g rat dosage, open distal end vascular clamp, suppository is injected.Then, folder closes common carotid artery distal end, extracts syringe needle, bonds pin hole with medical adhesive.Decontrol the vascular clamp of common carotid artery distal end, proximal part, external carotid artery after 1 minute successively, recover blood flow, cleaning wound, skin suture.
Medicine affects the hemorheology of different time after cerebral infarction: rat is divided into 2 hours groups, 3 days groups, 9 days groups, often group is further divided into administration group (application medicine 1 ~ 3 group or control drug 1 ~ 3 group+animal model group), normal saline group (normal saline+animal model group), sham operated rats (matched group), often organizes 12 rats.Administration group, normal saline group impose operation technique all as stated above, and sham operated rats operation technique is identical, but not injected plug agent, replace suppository with normal saline, be injected in internal carotid artery.
Administration group is in operation consent 3 days oral drugs (the application's medicine, control drug) 1.42g/Kg.Positive drug is in operation consent 1 hour intraperitoneal injection of drugs 1.0mg/Kg.Normal saline group injects commensurability normal saline.Sham operated rats does not inject any medicine.Every morning administration 1 time after 3 days groups and 9 days groups, for three days on end or 9 days.
2 hours after surgery, the 3rd day, the 9th day respectively, by rat anesthesia (25% urethane 0.3ml/100g body weight, lumbar injection), right common carotid artery blood-letting, in heparin test tube, measured the whole blood viscosity under different shear rate with cone and plate viscometer in 2 hours.Again that whole blood is centrifugal with 1500rpm, suck upper plasma.Then 0.25% bovine serum albumin-ringer solution rinsing erythrocyte three times is used, centrifugal 10 minutes of each 1500rpm.Finally, be in vitro mixed with erythrocyte at scale: albumen appoints the red blood cell protein ringer solution of liquid=6:4, measure its viscosity at 20 seconds under-1 shear rate.Using red blood cell protein ringer solution viscosity as erythrocyte deformability.All experiments are all carried out under 25 DEG C of constant temperature, carry out statistical test to experimental result.Concrete numerical value and the results are shown in Table one, table two.
Table one: the whole blood viscosity of different time after rat cerebral infarction is affected (unit: mPa.s)
From table one result of the test, after blocking latter 2 hours, whole blood viscosity respectively organizes equal no significant difference.When blocking 3 days, normal saline group is compared with sham operated rats, and whole blood viscosity rises (P<0.05), and animal model modeling success is described.Each administration group all can reduce whole blood viscosity to some extent, and wherein with the application's effect of drugs best (P<0.01, compared with normal saline group), control drug effect is taken second place.When blocking after 9 days, normal saline group is still abnormality with sham operated rats ratio, hemorheology, and whole blood viscosity increases the weight of further.Each administration group and normal saline group ratio, whole blood viscosity declines, and statistical procedures has significant, and wherein with the application's effect of drugs best (P<0.01), control drug effect is taken second place.
Table two: on the impact (unit: mPa.s) of different time erythrocyte-albumen ringer solution viscosity
From table two result of the test, after blocking latter 2 hours, normal saline group and administration group erythrocyte deformability decline, and each administration group is slightly lower than normal saline group numerical value, but effect is very unobvious.When blocking 3 days, normal saline group is compared with sham operated rats, and erythrocyte deformability declines further, all can erythrocyte deformability be stoped to a certain extent to decline in each administration group, the application's effect of drugs best (P<0.01).When blocking after 9 days, normal saline group and sham operated rats ratio, erythrocyte deformability further declines.Each administration group and normal saline group ratio, all can improve and stop the decline of erythrocyte deformability, statistical procedures has significant (P<0.01), wherein can strengthen erythrocyte deformability with the application's medicine.
In sum, perform the operation after 2 hours, rat has hemorheological exception.Infraction 3-9 days, Abnormal Blood Rheology increases the weight of further, shows as whole blood viscosity and raises, degradation under erythrocyte deformability.The application's medicine can play and improve hemorheological property effect after cerebral infarction, after the 3rd day, then can correct abnormal hemorheology change significantly.And successful is better than control drug, be also better than commercially available Breviscapini injection.
Test two: on senile rat in the thrombotic impact of body
Principle: use unidirectional current continued stimulus common carotid artery 7 minutes, cause blood vessel internal membrane damage, activate platelet and blood coagulation system, simultaneously vascular endothelial cell injury, makes the synthesis of PGI2 and release reduce, causes in carotid artery vascular and form mixed thrombus gradually.When carotid artery vascular endogenous cause of ill thrombosis during plug flow, then blood vessel distal temperature bust.By temperature sensor monitors blood vessel surface variations in temperature, by instrument automatic alarm, record to sudden temperature drop required time from stimulation, claim duration of congestion OT, i.e. thrombus formation time.Time is shorter, represents and more easily forms thrombosis; Otherwise the time is longer, represents and more not easily form thrombosis.
Senile rat can self-assembling formation blood stasis body constitution, easily forms thrombus in vivo.Young rat then not easily forms thrombosis.Therefore be positive control with senile rat in test, take young rat as negative control.
Material: male rat.Younger group Mus 3-4 in the age month, about body weight 250g.Old group Mus 24-27 in the age month, about body weight 500g.Equipment: rat operation platform, operating scissors, ophthalmic tweezers, mosquito forceps, mosquito clamp, rat oral gavage syringe needle, instrument for detecting internal thrombosis.Medicine and reagent: the application's medicine and control drug are with test one, and dosage is 1.42g/Kg; 20mg/ml Nembutal sodium solution; Normal saline.
Method: only give experimental group every day old group rat oral gavage 2ml/, positive controls senile rat and negative control group young rat gavage distilled water 2ml/ only, continuous 14 days.Drug withdrawal fasting on the same day.Lumbar injection 20mg/ml pentobarbital sodium 0.2ml/100g next day (body weight).Cut skin of neck, be separated right carotid artery, transfer stimulating electrode at carotid artery near-end, far-end transfers the temperature gauge head connecting instrument.Open instrument switch, give 1.5mV galvanic stimulation 7 minutes to damage carotid artery endotheliocyte by stimulating electrode, along with carotid canal intracavity thrombosis is formed gradually, blood flow is blocked gradually, and the temperature of carotid artery far-end declines gradually.When blood flow blocks completely, sudden temperature drop, instrument alarm, display duration of congestion OT, the OT time is shorter, more easily forms thrombosis; The OT time is longer, more not easily forms thrombosis.
Statistical test is carried out to experimental result.Concrete numerical value and the results are shown in Table three.
Table three: on senile rat in the thrombotic impact of body
From table three result of the test, senile rat OT is obviously short compared with young rat, illustrates and easily forms thrombosis.Administration group all can significant prolongation OT, and the application's effect of drugs better (P<0.01).
Above result shows, the application's medicine is effective compared with control drug.
Below in conjunction with detailed description of the invention, the present invention is described in further detail.Percentage ratio not specified in the present invention is all weight percentage.
Embodiment 1
Get Fructus Choerospondiatis 9kg, Herba Erigerontis 3kg, Fluoritum 6kg, Stigma Croci 3kg, Folium Ginseng 15kg, after pulverizing 40 mesh sieves respectively, mix homogeneously, makes capsule.
Embodiment 2
Obtain mixed powder by the method for embodiment 1, make capsule casing material with gelatin, be pressed into soft capsule.
Embodiment 3
By Fructus Choerospondiatis 20kg, Herba Erigerontis 6kg, Stigma Croci 6kg, Folium Ginseng 30kg alcohol reflux, extracting solution is concentrated into dry, obtains extract one.By Fluoritum 10kg pulverizing, cross 60 mesh sieves, obtain Fluoritum powder.By extract one and the mixing of Fluoritum powder, after adding the acceptable auxiliary element of pharmacy as required, drop pill preparation technology is adopted to obtain drops pharmaceutical composition.
Embodiment 4
Proportioning raw materials consumption is identical with embodiment 3, just Fructus Choerospondiatis, Herba Erigerontis, Stigma Croci and Radix Ginseng with 60% of 4 times of volumes alcohol reflux 3 hours, repeat extraction 4 times, extracting solution is concentrated into dry, obtains mixed extract one.All the other steps are also identical with embodiment 3.
Embodiment 5
Implementation process is with embodiment 4, and just raw material dosage is: Fructus Choerospondiatis 15kg, Herba Erigerontis 5kg, Fluoritum 8kg, Stigma Croci 5kg, Folium Ginseng 20kg.
Embodiment 6
Get Fructus Choerospondiatis 9kg, it is for subsequent use that pulverize at low temperature obtains Fructus Choerospondiatis powder.Get Herba Erigerontis 3kg, preferably through the preliminary Herba Erigerontis pulverized, add the high concentration ethanol of 4 times amount, reflux, extract, 2 times, each 1 hour, merge extractive liquid, reclaimed ethanol to paste, add 0.1% sodium hydroxide to dissolve, filter, the saturated n-butanol extraction of filtrate water.After water layer regulates pH=3, then with water-saturated n-butanol extraction, merge n-butyl alcohol liquid, be concentrated into dry, obtain Herba Erigerontis extract.Get Fluoritum 6kg, pulverizing, cross 60 mesh sieves, obtain Fluoritum powder for subsequent use.Get Stigma Croci 3kg, add the dense ethanol of 2 times of volumes, 70 DEG C of heating extraction 1.5 hours, repeat extraction 4 times, merge extractive liquid, reclaim ethanol, centrifugal, discard precipitation, are evaporated to by supernatant dry, obtain Stigma Croci extract.Folium Ginseng 15kg, add the soak by water 5 times of 10 times of volumes, each 2 hours, collecting decoction, was concentrated into 1/3 volume, and add ethanol to ethanol content 40%, hold over night or centrifugal, precipitation discards, and supernatant is evaporated to dry, both extract of Radix Ginseng leaf.The various extracts obtained through above-mentioned steps process are mixed in proportion, make capsule.
Embodiment 7
Get Fructus Choerospondiatis 5kg, Herba Erigerontis 1kg, Fluoritum 3kg, Stigma Croci 1kg, Folium Ginseng 10kg, implementation process, with embodiment 6, adds appropriate forming agent, binding agent tabletted.
Embodiment 8
Get Fructus Choerospondiatis 9kg, it is for subsequent use that pulverize at low temperature obtains Fructus Choerospondiatis powder.Get Herba Erigerontis 3kg, preferably through the preliminary Herba Erigerontis pulverized, add the high concentration ethanol of 6 times amount, reflux, extract, 1 time, each 2 hours, merge extractive liquid, reclaimed ethanol to paste, add 0.1% sodium hydroxide to dissolve, filter, the saturated n-butanol extraction of filtrate water.After water layer regulates pH=3, then with water-saturated n-butanol extraction, merge n-butyl alcohol liquid, be concentrated into dry, obtain Herba Erigerontis extract.Get Fluoritum 6kg, pulverizing, cross 60 mesh sieves, obtain Fluoritum powder for subsequent use.Get Stigma Croci 3kg, add the dense ethanol of 2 times of volumes, 70 DEG C of heating extraction 2 hours, repeat extraction 5 times, merge extractive liquid, reclaim ethanol, centrifugal, discard precipitation, are evaporated to by supernatant dry, obtain Stigma Croci extract.Folium Ginseng 15kg, add the soak by water 3 times of 10 times of volumes, each 1 hour, collecting decoction, was concentrated into 1/5 volume, and add ethanol to ethanol content 60%, hold over night or centrifugal, precipitation discards, and supernatant is evaporated to dry, both extract of Radix Ginseng leaf.The various extracts obtained through above-mentioned steps process are mixed in proportion, add the acceptable adjuvant of appropriate pharmacy and make tablet.
Embodiment 9
Use the extract mixtures identical with embodiment 8, be prepared into capsule.
Claims (4)
1. treat a pharmaceutical composition for cardiovascular and cerebrovascular disease, it is characterized in that being prepared from primarily of Fructus Choerospondiatis, Herba Erigerontis, Fluoritum, Stigma Croci, Folium Ginseng.
2. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 1, it is characterized in that the ratio of each component is: Fructus Choerospondiatis 1-20 part, Herba Erigerontis 1-6 part, Fluoritum 1-10 part, Stigma Croci 1-6 part, Folium Ginseng 1-30 part.
3. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 2, it is characterized in that the ratio of each component is: Fructus Choerospondiatis 5-15 part, Herba Erigerontis 1-5 part, Fluoritum 3-8 part, Stigma Croci 1-5 part, Folium Ginseng 10-20 part.
4. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 3, it is characterized in that the ratio of each component is: Fructus Choerospondiatis 9 parts, Herba Erigerontis 3 parts, Fluoritum 6 parts, Stigma Croci 3 parts, Folium Ginseng 15 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626346.2A CN104367725A (en) | 2014-11-10 | 2014-11-10 | Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626346.2A CN104367725A (en) | 2014-11-10 | 2014-11-10 | Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104367725A true CN104367725A (en) | 2015-02-25 |
Family
ID=52547085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626346.2A Pending CN104367725A (en) | 2014-11-10 | 2014-11-10 | Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367725A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004091645A2 (en) * | 2003-04-08 | 2004-10-28 | Herbalscience, Llc | Composition comprising rosmarinic acid, borneol and ginsenoside |
| CN102940658A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN102961517A (en) * | 2012-10-31 | 2013-03-13 | 成都医路康医学技术服务有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease |
-
2014
- 2014-11-10 CN CN201410626346.2A patent/CN104367725A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004091645A2 (en) * | 2003-04-08 | 2004-10-28 | Herbalscience, Llc | Composition comprising rosmarinic acid, borneol and ginsenoside |
| CN102940658A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN102961517A (en) * | 2012-10-31 | 2013-03-13 | 成都医路康医学技术服务有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease |
Non-Patent Citations (1)
| Title |
|---|
| 兰水中等: "《常见病单味中药新用》", 31 May 2013 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103393760A (en) | Externally-applied drug for treating rhinitis | |
| CN103768567A (en) | Black plaster and preparation method thereof | |
| CN104623433A (en) | Traditional Chinese medicine for preventing postanesthesia shivering and preparation method of traditional Chinese medicine | |
| CN101732389A (en) | Chinese medicinal composition for treating traumatic injury and promoting fracture healing and preparation method thereof | |
| CN104055909A (en) | Application of compound donkey-hide gelatin pulp in preparation of medicament for menstrual period health care | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN105616992A (en) | Medicine for anesthesia and relieving pain and preparation method thereof | |
| CN105412867A (en) | Chinese and western medicine for gynecology and obstetrics surgery and preparation method thereof | |
| CN104587166A (en) | Traditional Chinese medicine preparation for treating postpartum, and preparation method | |
| CN104367656A (en) | Hawthorn leaf-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104367630A (en) | American ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN103623361B (en) | Be used for the treatment of the Chinese medicine composition of cerebral thrombosis | |
| CN104435664A (en) | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104367725A (en) | Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN105796927B (en) | A kind of Chinese medicine composition for treating blepharospasm | |
| CN102940657A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN104490186A (en) | Traditional Chinese medicine pillow with function of reducing blood pressure | |
| CN104435843A (en) | Local anesthetic for surgical incisions | |
| CN104398664A (en) | Zhuang pharmaceutical composition for treating anovulatory infertility | |
| CN105079204B (en) | A kind of drug and preparation method thereof for treating rheumatic and rheumatoid arthritis | |
| CN104435106A (en) | Medicine composition containing salviae miltiorrhizae for treating cardiovascular and cerebrovascular diseases | |
| CN103520415A (en) | Medicament for treating traumatic injuries | |
| CN104435107A (en) | Rhizoma-chuanxiong-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN106266477A (en) | A kind of treat kidney yang deficiency, the pill medicine of soreness of the waist and knees that Qi and blood deficiency causes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150225 |